ArticleFrontiers in endocrinology2025
Predicting major cardiac and cerebrovascular events in acute coronary syndrome patients using the thyroid hormone sensitivity index.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex-specific associations between obstructive sleep apnea and thyroid hormone sensitivity in euthyroid adults.Biology of sex differences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: The thyroid hormone sensitivity index provides a new perspective for investigating nuanced alterations in thyroid function in cardiovascular disorders. However, the predictive value of thyroid hormone sensitivity indices for adverse events following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients remains unknown. This study aimed to investigate the predictive value of thyroid sensitivity indices for major adverse cardiac and cerebrovascular events (MACCEs) in these patients. Methods and results: A total of 431 patients were included in the analysis. Thyroid hormone sensitivity indices were calculated using the thyroid-stimulating hormone index (TSHI), thyrotrophic thyroxine resistance index (TT4RI), thyroid feedback quantile-based index (TFQI), and parametric thyroid feedback quantile-based index (PTFQI). During the median follow-up period, 50 (11.60%) patients experienced MACCEs. Multivariate Cox regression analysis revealed that TSHI (HR 1.277, 95% CI 1.110-1.468, P<0.001), TT4RI (HR 1.002, 95% CI 1.001-1.003, P<0.001), TFQI (HR 1.130, 95% CI 1.043-1.224, P=0.003), and PTFQI (HR 1.237, 95% CI 1.107-1.383, P<0.001) were independent predictors of MACCEs. The area under the ROC curve (AUROC) revealed that PTFQI had the highest predictive value (AUROC =0.688, 95% CI: 0.595-0.780; P < 0.001). Adding PTFQI to the GRACE score can enhance the risk prediction of MACCEs in ACS patients undergoing PCI, AUROC = 0.759 (95% CI 0.676-0.842, P < 0.001) vs AUROC = 0.646 (95% CI 0.563-0.729, P = 0.001), and there is a significant difference (P = 0.0108). Subgroup analysis indicated that PTFQI had a more significant predictive value for MACCEs in males and patients with abnormal blood glucose. Conclusion: Thyroid hormone sensitivity indices are associated with a greater risk of MACCEs in patients with ACS following PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.